• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Director Behner Peter was granted 2,267 shares, increasing direct ownership by 15% to 17,476 units (SEC Form 4)

    6/4/25 4:05:13 PM ET
    $INKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $INKT alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Behner Peter

    (Last) (First) (Middle)
    149 FIFTH AVENUE, SUITE 500

    (Street)
    NEW YORK NY 10010

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    MiNK Therapeutics, Inc. [ INKT ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/02/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 06/02/2025 A 2,267 A $7.17(1) 17,476 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.
    By: /s/ Christine Klaskin, Attorney-in-Fact 06/04/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $INKT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INKT

    DatePrice TargetRatingAnalyst
    8/15/2025$35.00Neutral → Buy
    H.C. Wainwright
    7/14/2025Outperform → Mkt Perform
    William Blair
    1/24/2022$24.00 → $10.00Buy
    B. Riley Securities
    11/9/2021$24.00Buy
    B. Riley Securities
    11/9/2021$26.00Outperform
    Robert W. Baird
    11/9/2021Outperform
    William Blair
    11/9/2021$30.00Outperform
    Evercore ISI Group
    11/9/2021$26.00Outperform
    Baird
    More analyst ratings

    $INKT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Corvese Brian was granted 2,494 shares, increasing direct ownership by 6% to 47,151 units (SEC Form 4)

    4 - MiNK Therapeutics, Inc. (0001840229) (Issuer)

    6/4/25 4:05:16 PM ET
    $INKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Behner Peter was granted 2,267 shares, increasing direct ownership by 15% to 17,476 units (SEC Form 4)

    4 - MiNK Therapeutics, Inc. (0001840229) (Issuer)

    6/4/25 4:05:13 PM ET
    $INKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Kadlec Robert Peter was granted 1,883 shares, increasing direct ownership by 68% to 4,647 units (SEC Form 4)

    4 - MiNK Therapeutics, Inc. (0001840229) (Issuer)

    6/4/25 4:05:13 PM ET
    $INKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $INKT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results

    Cash runway extended to deliver clinical program in GVHD and Ph2 results in 2L Gastric CancerDepartment of Defense STTR Grant to advance INKTs in GVHD announced; program advancingNew clinical grant awarded to launch AgenT-797 in GvHD clinical trial; target initiation 2H2025 NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced financial results for the second quarter ended June 30, 2025, and provided a business update highlighting major clinical achievements, a strengthened balance sheet, and expanded funding to adva

    8/14/25 7:30:00 AM ET
    $INKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report

    NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its second quarter 2025 financial results before the market opens on Thursday, August 14, 2025. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call Dial-in numbers: 646-307-1963 (New York), 800-715-9871 (USA & Canada) Conferenc

    7/31/25 8:30:00 AM ET
    $INKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy

    NEW YORK, July 15, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies, today announced the publication of a peer-reviewed article titled "CAR-iNKT Cells: Redefining the Frontiers of Cellular Immunotherapy" in Frontiers in Immunology. The publication, authored by leading experts in iNKT biology, underscores the power of iNKT cells as the next-generation off-the-shelf platform for treating solid tumors—where conventional cell therapies have failed to deliver lasting results. "This publication highlights what sets MiNK apart," said Jennifer Buell, PhD, President an

    7/15/25 8:21:46 AM ET
    $INKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $INKT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    MiNK Therapeutics upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded MiNK Therapeutics from Neutral to Buy and set a new price target of $35.00

    8/15/25 8:13:07 AM ET
    $INKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    MiNK Therapeutics downgraded by William Blair

    William Blair downgraded MiNK Therapeutics from Outperform to Mkt Perform

    7/14/25 8:40:54 AM ET
    $INKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    B. Riley Securities reiterated coverage on MiNK Therapeutics with a new price target

    B. Riley Securities reiterated coverage of MiNK Therapeutics with a rating of Buy and set a new price target of $10.00 from $24.00 previously

    1/24/22 8:57:46 AM ET
    $INKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $INKT
    SEC Filings

    View All

    SEC Form S-8 filed by MiNK Therapeutics Inc.

    S-8 - MiNK Therapeutics, Inc. (0001840229) (Filer)

    8/14/25 4:28:49 PM ET
    $INKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by MiNK Therapeutics Inc.

    10-Q - MiNK Therapeutics, Inc. (0001840229) (Filer)

    8/14/25 4:17:50 PM ET
    $INKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    MiNK Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - MiNK Therapeutics, Inc. (0001840229) (Filer)

    8/14/25 7:35:28 AM ET
    $INKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $INKT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Agenus Inc bought $25,270 worth of shares (22,975 units at $1.10), increasing direct ownership by 0.11% to 21,772,863 units (SEC Form 4)

    4 - MiNK Therapeutics, Inc. (0001840229) (Issuer)

    10/16/23 5:49:39 PM ET
    $INKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Agenus Inc bought $16,380 worth of shares (15,001 units at $1.09), increasing direct ownership by 0.07% to 21,749,888 units (SEC Form 4)

    4 - MiNK Therapeutics, Inc. (0001840229) (Issuer)

    10/6/23 4:26:25 PM ET
    $INKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $INKT
    Leadership Updates

    Live Leadership Updates

    View All

    MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors

    NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics ((MiNK, NASDAQ:INKT), a clinical-stage company pioneering the development of allogeneic off-the-shelf, invariant natural killer T (iNKT) cell therapies, today announced the appointment of Dr. Robert Kadlec to its Board of Directors. Dr. Kadlec brings unparalleled expertise in biodefense, pandemic preparedness, and public health strategy, positioning MiNK to accelerate its innovative iNKT cell platform for addressing critical infectious diseases, including pathogen-agnostic acute respiratory distress syndrome (ARDS), emerging threats, and immune related diseases. Dr. Kadlec recently served as the U.S. Senate-confirmed Assistant

    10/31/24 9:15:00 AM ET
    $INKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer

    Financing of $5.8 Million at a 25% premium will help advance the clinical development of MiNK-215, an armored-FAP-CAR-iNKTGKCC, LLC joins as a new investor with Katie Chudnovsky appointed as a Board Observer NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that it has entered into a stock purchase agreement to sell securities in a private placement financing (PIPE) for $5.8 million. This capital injection is e

    5/13/24 7:30:00 AM ET
    $INKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $INKT
    Financials

    Live finance-specific insights

    View All

    MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results

    Cash runway extended to deliver clinical program in GVHD and Ph2 results in 2L Gastric CancerDepartment of Defense STTR Grant to advance INKTs in GVHD announced; program advancingNew clinical grant awarded to launch AgenT-797 in GvHD clinical trial; target initiation 2H2025 NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced financial results for the second quarter ended June 30, 2025, and provided a business update highlighting major clinical achievements, a strengthened balance sheet, and expanded funding to adva

    8/14/25 7:30:00 AM ET
    $INKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report

    NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its second quarter 2025 financial results before the market opens on Thursday, August 14, 2025. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call Dial-in numbers: 646-307-1963 (New York), 800-715-9871 (USA & Canada) Conferenc

    7/31/25 8:30:00 AM ET
    $INKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress

    Clinical data builds with CR in testicular cancer, enrollment in Phase 2 gastric trial, and new data in PD-1–resistant tumors Near-term capital transactions poised to bolster liquidity NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced its financial results for the first quarter of 2025 and provided a business update highlighting continued clinical progress and strategic developments across its iNKT platform. The company will host a conference call and webcast today at 8:30 a.m. ET. "This

    5/15/25 7:30:00 AM ET
    $INKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $INKT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by MiNK Therapeutics Inc.

    SC 13G - MiNK Therapeutics, Inc. (0001840229) (Subject)

    5/22/24 4:33:15 PM ET
    $INKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D filed by MiNK Therapeutics Inc.

    SC 13D - MiNK Therapeutics, Inc. (0001840229) (Subject)

    2/14/24 6:05:43 PM ET
    $INKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by MiNK Therapeutics Inc. (Amendment)

    SC 13D/A - MiNK Therapeutics, Inc. (0001840229) (Subject)

    5/26/23 5:03:14 PM ET
    $INKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care